Virtual Conference
Otorhinolaryngology Conference 2022

Francisco Leandro Loiacono

Ushuaia Medical Center, Argentina

Title: Smell disorders caused by COVID19, Emerging treatment


Numerous cases of post-COVID19 olfactory disorders (hyposmia, anosmia, and later dysosmias) have been reported. SARS-CoV-2 viral particle persistence and associated inflammation in the olfactory neuroepithelium may account for prolonged loss of smell.
The pharmacological treatments tested during 2020 and 2021 were nasal corticosteroids, oral corticosteroids, thioctic acid, vitamin B complex, although they were not effective in most patients. Of these, only a small percentage improved, which could correspond to those who heal on their own regardless of any treatment. In September 2021, there was the fortuitous observation of a case of severe hyposmia of 16 months of evolution after COVID19 which was treated with FUSIMED B®, an oil-in-water emulsion of fusidic acid 2% and betamethasone 0.1%, for another diagnosis (epistaxis due to dry mucosa) with complete recovery of the smell within two weeks. This motivated us to develop a protocol for the treatment of post-Covid19 smell disorders, to evaluate its effectiveness.
A Study Case–Control for olfactory disorders post- COVID19 is presented. The results in this protocol showed efficacy in 80% of the cases in which the treatment was administered.